US 7,807,155 · Application 11/658,344 · Granted Oct 5, 2010
US 7,807,155
Il-17 antagonistic antibodies
Estimated expiration
July 26, 2027
263 days remaining
- Could not fetch continuity data for application PCTEP2005008470: Resource not found (404)
Earliest effective filing
Aug 4, 2005
+ 20 years
Aug 4, 2025
PTA +721d
Jul 26, 2027
No TD
—
Final
Jul 26, 2027
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.
Calculation details
Base term
- Filing date
- March 2, 2007
- Earliest effective filing
- August 4, 2005
- Issue date
- October 5, 2010
- PTA
- +721 days
- Base expiry (before PTA)
- August 4, 2025
August 4, 2005 + 20 years = August 4, 2025 + 721 PTA days = July 26, 2027
- National stage entry of application PCTEP2005008470, filed Aug 4, 2005
Terminal disclaimers
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
The prosecution record for your AI
Application 11/658,344 · US 7,807,155
You have the date. Your AI can have the file.
PatentReply compiles the prosecution history behind US 7,807,155: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One new public application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US7807155Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.